Funding

Triveni Bio

United States · Biotech

Develops novel antibody treatments for immunological and inflammatory disorders

Visit triveni.bioFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$65MAlexandria Venture — Role not disclosedAscenta Capital — Role not disclosedAtlas Venture — Role not disclosedDeep Track Capital — Role not disclosedFidelity — Role not disclosedGoldman Sachs — Role not disclosedJanus Henderson Investors — Role not disclosed

Investors

Alexandria VentureSeries CAscenta CapitalSeries CAtlas VentureSeries CDeep Track CapitalSeries CFidelitySeries CGoldman SachsSeries CJanus Henderson InvestorsSeries C

Coverage

Jun 17, 2026Triveni Bio · Series C

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcestriveni.bio ↗